Biogen  logo
Biogen BIIB
$ 197.11 0.82%

Annual report 2025
added 02-06-2026

report update icon

Biogen Financial Ratios 2011-2026 | BIIB

Annual Financial Ratios Biogen

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

22.7 11.9 16.6 13.3 20.2 11.0 8.8 15.2 29.5 16.3 17.8 31.3 40.5 26.7 22.9

P/S

3.0 2.0 2.0 4.0 2.9 3.3 3.6 5.0 6.1 5.3 5.9 9.5 10.9 6.7 5.6

EPS

8.8 11.2 8.0 21.0 10.4 24.9 31.5 21.6 11.9 17.0 15.4 12.4 7.9 5.8 5.1

EV (Enterprise Value)

37.6 B 28.3 B 30.2 B 48.2 B 42.1 B 56.5 B 62.9 B 78.2 B 84.4 B 68.7 B 71.8 B 94.3 B 78 B 39.5 B 30.4 B

EBITDA per Share

5.32 4.62 3.42 3.57 3.27 2.84 40.2 32.9 29.8 27.6 23.4 18.6 12 8.58 8.05

EV/EBITDA

12.7 11.8 7.3 10.7 12.5 10.7 12.6 20.7 26.6 18.4 14.8

PEG

1.62 -1.57 -1.63 -1.84 -2.7 -1.6 0.19 0.19 -1.0 1.58 0.75 0.54 1.14 1.92 0.82

P/B

1.6 1.2 1.3 3.0 2.9 4.1 3.9 5.2 6.0 5.0 6.7 8.5 8.7 5.3 4.4

P/CF

13.3 6.7 12.4 29.2 8.6 10.4 8.1 12.7 29.0 15.9 20.5 34.7 -64.8 22.8 19.2

ROE %

7.08 9.76 7.85 22.76 14.28 37.44 44.14 34.00 20.15 30.53 37.84 27.14 21.60 19.82 19.21

ROA %

4.39 5.82 4.33 12.41 6.52 16.25 21.62 17.52 10.73 16.19 18.19 20.50 15.70 13.62 13.64

ROCE %

- - - - - - 31.45 27.28 27.25 29.05 29.63 32.38 24.64 21.70 21.43

Current Ratio

2.6 2.5 2.2 2.2 1.8 1.8 1.7 2.3 2.3 2.6 2.6 2.1 1.8 2.0 3.3

DSO

50.7 57.9 62.5 58.4 57.6 51.5 62.7 67.4 69.0 55.5 52.3 59.3 56.7 63.2 58.8

DIO

351.4 394.0 278.9 216.0 209.4 189.3 150.1 186.9 202.1 247.2 262.9 250.6 280.4 299.3 255.6

DPO

65.0 65.4 64.5 86.6 90.3 99.7 99.1 74.5 88.6 69.1 78.7 71.4 93.6 136.5 145.8

Operating Cycle

402.0 451.9 341.4 274.3 266.9 240.8 212.8 254.3 271.1 302.8 315.2 309.9 337.1 362.5 314.4

Cash Conversion Cycle

337.1 386.5 277.0 187.8 176.6 141.2 113.8 179.8 182.6 233.7 236.5 238.4 243.6 226.1 168.6

All numbers in USD currency

Quarterly Financial Ratios Biogen

2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

4.33 1.65 2.67 4.01 2.71 -0.47 4.09 2.69 - 7.86 7.25 2.06 - 2.22 3 5.7 2.33 4.47 9.6 8.1 8.1 8.4 7.85 7.17 4.74 7.17 4.18 5.55 -1.41 5.8 4.07 3.47 3 4.72 4.79 4.44 3.77 4.16 3.94 3.5 3.75 3.63 3.02 2.03 1.94 2.06 2.07 1.8 1.24 1.68 1.62 1.26 1.24 1.45 1.19 1.22

EBITDA per Share

- - - - - - - - - 0.44 0.46 5.12 - 7.75 3.61 7.92 - 9.14 13.7 11.2 - 12.9 11.5 8.26 - 11.8 7.5 8.06 - 11.9 8.95 7.13 - 8.82 8.15 6.98 - 7.82 6.48 5.39 - 7.13 5.68 3.64 - 4.46 3.74 2.57 - 3.4 2.85 1.89 - 3.12 2.45 2.11

ROE %

11.06 10.05 8.16 9.88 9.02 15.32 24.68 29.51 20.51 23.54 17.68 12.93 15.08 18.42 21.95 32.19 37.39 44.83 49.86 46.65 44.13 40.60 40.09 35.54 33.98 24.36 23.00 23.20 20.13 27.84 26.62 28.43 30.50 34.03 35.82 37.07 37.84 37.14 34.77 31.49 27.15 24.28 22.01 21.09 21.60 20.49 20.56 20.43 19.82 20.30 20.05 18.98 19.21 5.48 4.48 4.58

ROA %

6.65 5.89 4.79 5.77 5.17 8.25 13.06 14.93 10.07 11.45 8.27 5.88 6.81 8.27 9.73 14.16 16.25 20.08 22.91 22.13 21.62 20.08 20.11 18.06 17.52 12.52 11.99 12.21 10.73 14.83 14.16 15.10 16.19 17.61 18.05 18.21 18.19 20.09 21.13 21.37 20.50 18.18 16.31 15.45 15.70 14.73 14.55 14.23 13.62 14.06 14.01 13.38 13.64 3.89 3.18 3.25

ROCE %

- - - - - - - 5.44 10.89 18.18 20.04 24.55 20.75 30.90 33.76 47.70 45.61 59.15 62.54 58.74 39.46 52.48 51.96 46.60 34.09 47.21 47.30 47.52 30.76 42.50 41.13 43.64 35.12 49.76 52.66 53.78 39.72 50.38 46.41 42.40 26.02 33.96 31.24 29.78 21.55 29.24 28.99 28.56 20.26 27.86 27.78 26.90 20.47 7.60 6.39 6.48

Current Ratio

2.6 2.5 2.4 2.5 2.3 2.1 2.4 2.3 2.2 2.1 1.9 1.9 1.9 1.8 1.9 1.9 1.8 1.8 1.8 1.8 2.0 2.0 2.0 2.0 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 1.9 1.9 1.9 1.9 4.1 4.1 4.1 4.1 3.7 3.7 3.7 3.7 3.2 3.2 3.2 3.2 3.5 3.5 3.5 3.5

DSO

- - - - - - - 61.9 - 57.0 56.4 57.3 - 56.0 53.2 28.9 61.2 51.7 47.4 49.0 46.7 47.7 47.5 50.2 50.7 52.0 53.2 54.6 49.3 53.0 53.0 52.4 45.8 44.5 45.5 44.6 39.4 40.3 43.2 45.0 44.7 47.0 48.7 45.4 38.3 41.2 43.6 48.7 44.2 45.2 44.1 44.9 40.2 40.7 44.1 -

DIO

343.0 343.9 355.4 419.7 462.8 298.5 201.3 180.7 - 259.4 236.6 155.3 - 232.0 258.7 117.7 - 217.1 237.2 188.1 - 170.7 154.1 131.4 - 184.1 201.6 187.5 - 222.6 224.9 - - - - - - - - - - - - - - - - 377.4 - 292.9 293.4 265.2 - 241.4 296.8 -

DPO

60.3 59.0 55.5 62.0 69.6 61.2 72.1 67.7 - 79.5 78.6 59.8 - 71.6 95.7 50.8 - 92.4 101.0 99.0 - 112.6 101.7 68.3 - 73.4 80.3 78.4 - 97.5 98.5 - - - - - - - - - - - - - - - - 144.6 - 133.6 133.8 133.7 - 137.7 169.3 -

Operating Cycle

343.0 343.9 355.4 419.7 462.8 298.5 201.3 242.6 - 316.4 292.9 212.7 - 288.0 311.9 146.6 61.2 268.9 284.6 237.1 46.7 218.3 201.5 181.6 50.7 236.1 254.8 242.1 49.3 275.6 277.9 52.4 45.8 44.5 45.5 44.6 39.4 40.3 43.2 45.0 44.7 47.0 48.7 45.4 38.3 41.2 43.6 426.1 44.2 338.2 337.6 310.1 40.2 282.2 340.9 -

Cash Conversion Cycle

282.7 284.9 299.9 357.8 393.1 237.3 129.2 174.9 - 236.9 214.4 152.9 - 216.4 216.2 95.8 61.2 176.4 183.7 138.1 46.7 105.7 99.8 113.3 50.7 162.7 174.5 163.7 49.3 178.1 179.4 52.4 45.8 44.5 45.5 44.6 39.4 40.3 43.2 45.0 44.7 47.0 48.7 45.4 38.3 41.2 43.6 281.5 44.2 204.6 203.8 176.4 40.2 144.4 171.6 -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Biogen , allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
argenx SE argenx SE
ARGX
$ 831.0 -0.3 % $ 25 B niderlandNiderland
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 14.75 -0.74 % $ 6.01 B irlandaIrlanda
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
$ 4.12 5.07 % $ 351 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Adagene Adagene
ADAG
$ 3.17 11.23 % $ 178 M chinaChina
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.77 -10.2 % $ 4.2 M chinaChina
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.48 -0.83 % $ 8.37 B australiaAustralia
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 215.19 -1.33 % $ 5 B danmarkDanmark
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
$ 60.64 1.33 % $ 123 B usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 106.73 0.92 % $ 27.2 B germanyGermany
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.4 1.59 % $ 357 M britainBritain
Burford Capital Limited Burford Capital Limited
BUR
$ 9.35 0.54 % $ 1.51 B britainBritain
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 14.93 2.05 % $ 4.61 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA